Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$196.82 USD

196.82
2,946,862

-0.14 (-0.07%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why

AbbVie's (ABBV) shares have gained an impressive 16.7% in the past month supported by a series of positive news for the company in the past few weeks.

    Arpita Dutt headshot

    Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation

    Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.

      Arpita Dutt headshot

      Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?

      With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.

        Merck Drops Two HCV Combination Programs Amid Competition

        Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.

          Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China

          Gilead Sciences' (GILD) blockbuster hepatitis C virus (HCV) infection drug, Sovaldi is now approved in China also.

            Arpita Dutt headshot

            Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues

            Key highlights this week include Amgen's (AMGN) update regarding Hurricane Maria and safety issues concerning Intercept's Ocaliva.

              Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer

              AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.

                Gilead's (GILD) Epclusa Receives Label Expansion in Canada

                Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

                  Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.

                    Roche (RHHBY) Announces Positive Data on Leukemia Drug

                    Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.

                      J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU

                      J&J's (JNJ) pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis received a positive opinion from the CHMP in the EU.

                        Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx

                        Novartis' (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.

                          Arpita Dutt headshot

                          Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data

                          Key highlights include Alexion's (ALXN) restructuring plans and promising data from Kura Oncology on its lead pipeline candidate.

                            AbbVie's RA Candidate Meets Primary Endpoint in Phase III

                            AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.

                              AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb

                              AbbVie's (ABBV) eczema candidate upadacitinib meets primary endpoints in a phase IIb trial for treating atopic dermatitis. The company aims to advance the candidate to the next study level in 2018.

                                Regeneron's Cemiplimab Gains Breakthrough Therapy Status

                                Regeneron (REGN) and partner Sanofi's skin cancer candidate cemiplimab gets the FDA-granted Breakthrough Therapy status. The companies also anticipate submitting a BLA in the first-quarter 2018.

                                  AbbVie Inc. (ABBV) in Focus: Stock Moves 6.1% Higher

                                  AbbVie (ABBV) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.

                                    AbbVie Submits NDA for Endometriosis Candidate to the FDA

                                    AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.

                                      Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead

                                      The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.

                                        The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

                                        The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

                                          Gilead to Fly High with Kite Pharma Acquisition for $11.9B

                                          Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.

                                            The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance

                                            The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance

                                              Roche's Gazyva Gets Priority Review for Follicular Lymphoma

                                              Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.

                                                Biogen's Humira Biosimilar Imraldi Gets Approval in EU

                                                Biogen Inc.'s (BIIB) biosimilar version of AbbVie's top-selling blockbuster drug, Humira has been approved by the European Commission.

                                                  Roche (RHHBY) Hemophilia A Drug Granted Priority Review

                                                  Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.